INTRODUCTION AND OBJECTIVES: Local recurrence (LR)
after extirpative surgery for renal cell carcinoma (RCC) refers to cancer that has recurred at or near the site of the primary tumor. Currently, no existing definition of LR accounts for differences in location or extent of recurrence, and the potential prognostic implications of these differences are unknown. We describe a novel anatomic classification system for LR, and evaluate clinicopathologic risk factors associated with potential survival differences based on LR type.
METHODS: Recurrence data from the ASSURE (ECOG-ACRIN 2805) trial were queried for all patients with fully resected intermediate or high risk non-metastatic RCC with LR. All patients with concurrent metastasis (any extra-abdominal recurrence) at time of LR were excluded. The cohort was divided into four LR groups: CONCLUSIONS: Our anatomic classification system may be used to categorize LR based on location and extent of tumor burden. Although there was no difference in survival when LR was limited to a single anatomic subdivision, LR that involved multiple subdivisions (Type 4) was associated with worse survival.
Source of Funding: This study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820, CA180794, CA180867, CA180858, CA180888, CA180821, CA180863, and Canadian Cancer Society #704970.
MP14-19 SURVIVAL DIFFERENCES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE BASED ON POSITIVE AND NEGATIVE FAMILY HISTORY
Kaifang Ma*, Baoan Hong, Haibiao Xie, Kan Gong, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Von Hippel-Lindau (VHL) disease is an autosomal-dominant hereditary cancer syndrome occurring in approximately one in 36000 births. Although survival analysis of VHL patients has been described in some studies, the difference between positive family history and negative family history patients remain unclear. We aimed to assess survival differences of patients with VHL disease based on positive and negative family history.
METHODS: Patients who diagnosed with VHL disease (n[588) from 216 VHL families were recruited in this retrospective study. We divided patients based on family history: positive family history (PFH) patients (n[507) and negative family history (NFH) patients (n[81). Agerelated penetrance of the six major VHL lesions and survival analysis were calculated using Kaplan-Meier plot and Log-rank test.
RESULTS: VHL patients with positive family history had lower risks of central nervous system hemangioblastoma (HR[0.55, p[0.0007) figure 1) . Furthermore, the mean age of first presenting symptom in PFH group was 31.93 years (range 2-74 years), and NFH group was 28.46 years (range 10-54 years). The study also revealed that VHL disease showed high ageassociated penetrance in Chinese, the cumulative penetrance by 65 years was about 96.8%. And the median survival for Chinese patients with VHL disease was 61 years (figure 2).
CONCLUSIONS: This largest VHL survival analysis manifested that positive family history may be a protective factor of better survival in VHL patients, which is helpful to genetic counselling and clinical deci
